Tuesday, bioMerieux announced that it has entered into an agreement with GlaxoSmithKline plc (GSK: Quote, GSK.L) to co-develop a diagnostic test to find out optimum treatment for different segments of breast cancer patients. The company said that the test aims at using both adjuvant and metastatic breast cancer settings.
bioMerieux also said that both companies would co-found the future developments of the test that would leverage their complementary expertise. In addition, GlaxoSmithKline will bring its extensive experience in the field of cancer and in conducting clinical studies, and would also facilitate access to samples from several clinical trials under the collaboration.
The Marcy L'Etoile, France-based bioMerieux said that the new test will be developed by its global research and development team, including its subsidiary, bioTheranostics, which has a high complexity laboratory certified under the Clinical Laboratory Improvement Amendments or CLIA.
The bioTheranostics team has expertise in molecular oncology diagnostics, with its THEROS CancerTYPE ID test for identifying metastatic cancers of uncertain or unknown origin and THEROS Breast Cancer Index test for predicting breast cancer recurrence risk.
The company said that pursuant to the clinical evaluation, the test will be launched by bioTheranostics in its CLIA-certified laboratory, after which an in vitro diagnostic kit will be developed by bioMerieux and introduced to the global market leveraging the resources of bioMerieux and the collaboration.
Commenting on the venture, bioMerieux chief executive officer, Stephane Bancel said, "This new collaboration is a significant milestone in our theranostics strategy. Working with GSK, we hope to achieve an important breakthrough in breast cancer care, helping oncologists to determine the most appropriate treatment as early as possible to give a significant number of breast cancer patients the chance for a better outcome."
Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe and predictive tests have been shown to improve outcomes for these patients.
GSK is currently trading at $41.74, down $0.16 or 0.38%, on a volume of 820,645 shares, while GSK.L closed Tuesday's regular session at GBX 1,247.50, down GBX 3.50 or 0.28% on the London Stock Exchange.
by RTT Staff Writer
For comments and feedback: email@example.com